Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban

Gregory Y. H. Lip, Xianying Pan, Shital Kamble, Hugh Kawabata, Jack Mardekian, Cristina Masseria, Hemant Phatak

Research output: Contribution to journal › Article › peer-review

28 Citations (Scopus)
140 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Discontinuation risk comparison among ‘real-world’ newly anticoagulated atrial fibrillation patients: Apixaban, warfarin, dabigatran, or rivaroxaban'. Together they form a unique fingerprint.

Medicine & Life Sciences

Chemistry

Agriculture & Biology